Sai Life Sciences, one of the key players in the contract research, development, and manufacturing (CRDMO) sector, made its ...

MILAN, December 18, 2024--(BUSINESS WIRE)--XGEN Venture, a leading venture capital firm specializing in life sciences ...

Qualified Institutional Buyers (QIBs) led the demand for the issue, as their portion was subscribed to 30.93 times ...

The share price of Sai Life Sciences Ltd. ended on the BSE on Wednesday at Rs 768.4 apiece, a premium of 39.9% over the issue ...

Shares of Sai Life Sciences, contract research, development, and manufacturing organisation, will list on NSE and BSE at 10 ...

Sai Life Sciences shares surged 16% to Rs 764.4 on their BSE debut, opening at a premium of 18% over the IPO price. Analysts ...

When we learned about the BBBRC in 2021, North Carolina’s life sciences manufacturing was at a critical point. More than ...

The stock is listed at a premium of 20% on BSE, and at a premium above 18% on NSE. Experts advise investors to HOLD this ...

Sai Life Sciences shares debuted with a premium on NSE and BSE, exceeding market expectations. The IPO saw strong demand from institutional investors, while retail interest remained moderate. Experts ...

Sai Life Sciences, which is backed by the global private equity major TPG Capital, has raised Rs 912.78 crore from marquee ...

北京时间2024年12月13日01时53分，Atai Life Sciences N.V.（ATAI.us）股票出现异动，股价快速下挫5.07%。截至发稿，该股报1.41美元/股，成交量59.7044万股， 换手率 0.36%，振幅8.11%。

科罗拉多州威斯敏斯特市—TriSalus Life Sciences, Inc. (NASDAQ:TLSI)的董事Arjun JJ Desai最近出售了30,000股公司普通股。根据SEC文件报告，这笔交易发生于2024年12月10日，总价值约为110,700美元。